annual cash & cash equivalents:
$103.15M+$51.80M(+100.86%)Summary
- As of today (September 3, 2025), ADMA annual cash & cash equivalents is $103.15 million, with the most recent change of +$51.80 million (+100.86%) on December 31, 2024.
- During the last 3 years, ADMA annual cash & cash equivalents has risen by +$52.06 million (+101.90%).
- ADMA annual cash & cash equivalents is now at all-time high.
Performance
ADMA Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$90.28M+$18.66M(+26.05%)Summary
- As of today (September 3, 2025), ADMA quarterly cash & cash equivalents is $90.28 million, with the most recent change of +$18.66 million (+26.05%) on June 30, 2025.
- Over the past year, ADMA quarterly cash & cash equivalents has increased by +$2.04 million (+2.31%).
- ADMA quarterly cash & cash equivalents is now -12.47% below its all-time high of $103.15 million, reached on December 31, 2024.
Performance
ADMA quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ADMA Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +100.9% | +2.3% |
| 3 y3 years | +101.9% | +72.3% |
| 5 y5 years | +285.6% | +19.1% |
ADMA Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +101.9% | -12.5% | +158.7% |
| 5 y | 5-year | at high | +285.6% | -12.5% | +162.4% |
| alltime | all time | at high | >+9999.0% | -12.5% | >+9999.0% |
ADMA Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $90.28M(+26.1%) |
| Mar 2025 | - | $71.63M(-30.6%) |
| Dec 2024 | $103.15M(+100.9%) | $103.15M(+19.0%) |
| Sep 2024 | - | $86.71M(-1.7%) |
| Jun 2024 | - | $88.24M(+94.7%) |
| Mar 2024 | - | $45.33M(-11.7%) |
| Dec 2023 | $51.35M(-40.6%) | $51.35M(-30.8%) |
| Sep 2023 | - | $74.16M(+18.6%) |
| Jun 2023 | - | $62.51M(-9.7%) |
| Mar 2023 | - | $69.20M(-20.0%) |
| Dec 2022 | $86.52M(+69.4%) | $86.52M(+147.9%) |
| Sep 2022 | - | $34.91M(-33.4%) |
| Jun 2022 | - | $52.42M(-24.6%) |
| Mar 2022 | - | $69.50M(+36.0%) |
| Dec 2021 | $51.09M(-8.6%) | $51.09M(+48.5%) |
| Sep 2021 | - | $34.41M(-18.9%) |
| Jun 2021 | - | $42.41M(-31.6%) |
| Mar 2021 | - | $61.97M(+10.8%) |
| Dec 2020 | $55.92M(+109.0%) | $55.92M(-6.3%) |
| Sep 2020 | - | $59.67M(-21.3%) |
| Jun 2020 | - | $75.78M(-25.1%) |
| Mar 2020 | - | $101.24M(+278.4%) |
| Dec 2019 | $26.75M(+17.6%) | $26.75M(-44.3%) |
| Sep 2019 | - | $48.01M(-34.8%) |
| Jun 2019 | - | $73.62M(+345.2%) |
| Mar 2019 | - | $16.53M(-27.3%) |
| Dec 2018 | $22.75M | $22.75M(-46.3%) |
| Sep 2018 | - | $42.37M(-23.2%) |
| Jun 2018 | - | $55.15M(+99.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $27.62M(-38.1%) |
| Dec 2017 | $44.61M(+191.5%) | $44.61M(+228.0%) |
| Sep 2017 | - | $13.60M(-46.8%) |
| Jun 2017 | - | $25.57M(+191.0%) |
| Mar 2017 | - | $8.79M(-42.6%) |
| Dec 2016 | $15.31M(-8.9%) | $15.31M(-19.2%) |
| Sep 2016 | - | $18.93M(-20.5%) |
| Jun 2016 | - | $23.82M(+105.0%) |
| Mar 2016 | - | $11.62M(-30.9%) |
| Dec 2015 | $16.81M(-23.1%) | $16.81M(-19.7%) |
| Sep 2015 | - | $20.94M(-11.8%) |
| Jun 2015 | - | $23.75M(-15.4%) |
| Mar 2015 | - | $28.08M(+28.5%) |
| Dec 2014 | $21.85M(-24.9%) | $21.85M(+7.8%) |
| Sep 2014 | - | $20.27M(-16.2%) |
| Jun 2014 | - | $24.18M(-15.8%) |
| Mar 2014 | - | $28.72M(-1.3%) |
| Dec 2013 | $29.08M(+132.0%) | $29.08M(+440.6%) |
| Sep 2013 | - | $5.38M(-29.7%) |
| Jun 2013 | - | $7.65M(-25.8%) |
| Mar 2013 | - | $10.32M(-17.7%) |
| Dec 2012 | $12.54M(>+9900.0%) | $12.54M(+16.9%) |
| Sep 2012 | - | $10.72M(-16.8%) |
| Jun 2012 | - | $12.89M(-9.5%) |
| Mar 2012 | - | $14.24M(>+9900.0%) |
| Dec 2011 | $87.80K(-61.7%) | - |
| Mar 2011 | - | $16.20K(+422.6%) |
| Dec 2010 | $229.00K(+1808.3%) | $3100.00(-74.2%) |
| Jun 2010 | - | $12.00K |
| Jun 2010 | $12.00K | - |
FAQ
- What is ADMA Biologics, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ADMA Biologics, Inc.?
- What is ADMA Biologics, Inc. annual cash & cash equivalents year-on-year change?
- What is ADMA Biologics, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for ADMA Biologics, Inc.?
- What is ADMA Biologics, Inc. quarterly cash & cash equivalents year-on-year change?
What is ADMA Biologics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of ADMA is $103.15M
What is the all time high annual cash & cash equivalents for ADMA Biologics, Inc.?
ADMA Biologics, Inc. all-time high annual cash & cash equivalents is $103.15M
What is ADMA Biologics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, ADMA annual cash & cash equivalents has changed by +$51.80M (+100.86%)
What is ADMA Biologics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ADMA is $90.28M
What is the all time high quarterly cash & cash equivalents for ADMA Biologics, Inc.?
ADMA Biologics, Inc. all-time high quarterly cash & cash equivalents is $103.15M
What is ADMA Biologics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, ADMA quarterly cash & cash equivalents has changed by +$2.04M (+2.31%)